Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin for daytime sleep after permanent night shifts
2005-000120-17Phase 2Completed
- Sponsor
- Alliance Pharma
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, double-blind trial of melatonin in circadian rhythm sleep disorder (CRSD) (2 arms), sponsored by Alliance Pharma. Primary endpoint: Change in total sleep time. Started Feb 2005; status: completed.
02
Drugs
melatonin
03
Conditions
circadian rhythm sleep disorder (CRSD)
Beyond the preview
Go deeper on 2005-000120-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000120-17.